BackExact Sciences Overview
Exact Sciences Corp.

Exact Sciences Debt to Equity

Valuation check: EXAS's debt-to-equity ratio is 1.05, above the Healthcare sector average of 0.26.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

1.05

Debt to Equity

1.05

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Exact Sciences (EXAS) FAQ

Exact Sciences (EXAS) currently reports a debt-to-equity ratio of 1.05. That is above the Healthcare sector average of 0.26. Use the charts on this page to explore Exact Sciences's debt-to-equity ratio history and peer comparisons.

Exact Sciences's debt-to-equity ratio of 1.05 is higher than the Healthcare sector average of 0.26. That is roughly 297.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Exact Sciences's market price to a fundamental measure such as earnings, sales, or book value. At 1.05, EXAS can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 1.05, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.26. From there, open related valuation or income-statement pages for Exact Sciences, and consider following EXAS for alerts when major investors trade the stock.

Exact Sciences is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows 1.05 versus a sector average near 0.26. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EXAS with unrelated industries.